In late March 2013, DARA Bio (DARA) filed its Form 10K annual report highlighting both the business and financial updates from 2012. Below we discuss the key drivers at DARA, and why we believe the company is a vastly undervalued emerging specialty pharmaceutical story.
Smart Stocks Watch: Apricus Bio — Erectile Dysfunction, Anti-Fungals
The San Diego-based pharmaceutical company has five approved products internationally, covering erectile dysfunction (Vitaros), side effects of cancer therapy (Totect and Granisol), coronary artery disease (Nitromist) and dry mouth (Aquoral). After a series of successes in strategic partnerships, acquisitions, peer review and clinical data in Q3, the company is garnering some serious attention.
Your Biotech Calendar, August 28: PDUFA Dates, SEC Filings, Financings
At OneMedPlace, our goal is to be your eyes and ears to the biotech and life sciences sector: putting into perspective what we’ve seen so far, and providing you with snapshots of and what’s upcoming.
Bio-Path Holdings To Present Powerful Drug Delivery Technology at OneMedForum NY 2011
Bio-Path Holdings has developed a powerful drug delivery technology that utilizes cell-like drug carriers, termed liposomes, which avoid drug breakdown.
ADVENTRX Pharmaceuticals Takes the Next Step In Approval of ANX-530
ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX), with its leading innovations in anti-cancer drug development has just announced that they have been successful in sending their ANX-530 (Exelbine) New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) date of September 1, 2011.
Ligand to Buy Struggling Metabasis
Ligand Pharmaceuticals has agreed to buy the struggling Metabasis Therapeutics for $3.2 million in cash.